Prilosec OTC Exceeds Sales Expectations, Drags Down Healthcare Earnings
This article was originally published in The Tan Sheet
Executive Summary
Prilosec OTC sales have been a boon to Procter & Gamble's healthcare top line, but the product's successful launch has negatively impacted earnings a year after its debut
You may also be interested in...
P&G Thinks Globally, Acts Locally With Long-Term Growth Strategy
Procter & Gamble has its eye on broadening its reach in key developing markets as it pursues its comprehensive global growth strategy
P&G Thinks Globally, Acts Locally With Long-Term Growth Strategy
Procter & Gamble has its eye on broadening its reach in key developing markets as it pursues its comprehensive global growth strategy
P&G Thinks Globally, Acts Locally With Long-Term Growth Strategy
Procter & Gamble has its eye on broadening its reach in key developing markets as it pursues its comprehensive global growth strategy